End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,015 MXN | -3.16% |
|
-.--% | +8.91% |
Jul. 11 | Citigroup Adjusts Price Target on Zimmer Biomet to $120 From $134 | MT |
Jul. 11 | Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $120 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's enterprise value to sales, at 3.43 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.91% | 22.26B | - | ||
-5.31% | 181B | C+ | ||
-5.38% | 100B | C | ||
-6.04% | 65.01B | A | ||
+16.45% | 45.75B | B+ | ||
-8.08% | 44.8B | B- | ||
+8.38% | 43.72B | B- | ||
+12.06% | 29.01B | B | ||
+17.98% | 26.03B | A- | ||
-8.28% | 24.28B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZBH * Stock
- Ratings Zimmer Biomet Holdings, Inc.